PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 85% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer (NYSE:PFE) has had a rough month with its share price down 2.9%. It is possible that the markets have ignored the ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 ...

Shares of Pfizer PFE rose nearly 3% on Monday following a report issued by Bloomberg, which stated that activist investor Starboard did not nominate any director to Pfizer’s board ahead of Jan.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

Shares of Pfizer PFE rose nearly 3% on Monday following a report issued by Bloomberg, which stated that activist investor Starboard did not nominate any director to Pfizer’s board ahead of Jan. 25.